Tempus AI's biotech deal attracts investor attention
The deal would have passed by without much notice, but Personalis’ technology is crucial to building the revolutionary personalized cancer therapies announced earlier this week by Merck and Moderna.
Tempus AI's acquisition of Personalis for $1.5 billion has drawn significant investor interest, despite the deal having been announced only in July. Personalis, a Merck-backed biotech company, provides advanced genomic sequencing and analytics for cancer treatments. The company's technology is vital to Merck's and Moderna's announcement of groundbreaking personalized cancer therapies, increasing the value of Personalis' technology and influencing the decision to acquire the company.
Following the deal announcement, shares of both Tempus AI and Personalis experienced a sharp rise. Personalis' stock surged by 22% since Tuesday, while Tempus AI's stock also increased. Investors are betting on the deal being renegotiated, but observers and investors believe it is unlikely for Personalis or its parent company, Merck, which holds a 13% stake, to change the terms. Merck declined to comment on the subject.
Given the recent news about the treatments, Merck's M&A team might consider acquiring Personalis to leverage the company's technology. The recent surge in Merck and Moderna's market capitalizations has given them a stronger position and more valuable currency to pursue strategic moves.
Written by urgent.news from Semafor's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
